First Time Loading...

ADC Therapeutics SA

Watchlist Manager
ADC Therapeutics SA Logo
ADC Therapeutics SA
Price: 0.83 USD Market Closed
Updated: Oct 1, 2023

Intrinsic Value

Intrinsic Value History
ADC Therapeutics SA

Whether you're assessing long-term stability or short-term opportunities, Historical Valuation serves as a vital tool to enhance your investment approach, enabling you to make more informed investment decisions.

This feature available only with
Unlimited Plan

Sign up to access ADC Therapeutics SA's intrinsic value history.

No restrictions, no limits.
All stocks, all tools.

Spot Contrarian Opportunities

Look for stocks that have been historically overvalued but are now trading below their intrinsic value.

Easily Identify Value Traps

Avoid stocks that are always undervalued and never reach their intrinsic value.

Find Strong Rebounds

Find stocks that have historically corrected quickly from being undervalued to reaching their intrinsic value.

Valuation Methods

There are two methods to calculate the Intrinsic Value of a stock: DCF Valuation and Relative Valuation. We take the average of these two methods to estimate the intrinsic value as accurately as possible. You can see the Intrinsic Value of a stock at the top of this page.

DCF Value
Discounted Cash Flow

DCF Parameters:
Operating Model
Discount Rate
Forecast Period
Terminal Growth
DCF Input
DCF Input
DCF Input

Fundamental Analysis


Balance Sheet Decomposition
ADC Therapeutics SA

Current Assets 413m
Cash & Short-Term Investments 348m
Receivables 23.9m
Other Current Assets 41.4m
Non-Current Assets 94.5m
Long-Term Investments 28.3m
PP&E 16.4m
Intangibles 13.5m
Other Non-Current Assets 36.3m
Current Liabilities 80.6m
Accounts Payable 11.7m
Other Current Liabilities 68.9m
Non-Current Liabilities 435m
Long-Term Debt 407m
Other Non-Current Liabilities 27.9m
Fundamental Scores

ADCT Profitability Score
Profitability Due Diligence

ADC Therapeutics SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.


ADC Therapeutics SA's profitability score is 23/100. The higher the profitability score, the more profitable the company is.

ADCT Solvency Score
Solvency Due Diligence

ADC Therapeutics SA's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Positive Net Debt
Long-Term Solvency
High D/E

ADC Therapeutics SA's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

ADCT Price Targets Summary
ADC Therapeutics SA

Wall Street analysts forecast ADCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for ADCT is 8.17 USD .

Price Target
Not Available
Price Target
8.17 USD
884% Upside
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

ADCT Return Decomposition
Main factors of price return

What is price return decomposition?

ADCT Price
ADC Therapeutics SA

1M 1M
6M 6M
1Y 1Y
3Y 3Y
5Y 5Y
10Y 10Y
Annual Price Range
52w Low
52w High
Price Metrics
Average Annual Return -15.11%
Standard Deviation of Annual Returns 33.63%
Max Drawdown -99%
Shares Statistics
Market Capitalization 66.9m USD
Shares Outstanding 80 642 527
Percentage of Shares Shorted 11.87%

Company Profile

ADC Therapeutics SA Logo
ADC Therapeutics SA





Market Cap

66.9m USD

Dividend Yield



ADC Therapeutics SA is a clinical-stage biotechnology company. The company is headquartered in Epalinges, Vaud and currently employs 312 full-time employees. The company develops antibody drug conjugates (ADCs) for the treatment of both solid and hematological cancers. The company employs monoclonal antibodies specific to particular tumor antigens conjugated to a class of pyrrolobenzodiazepine (PBD)-based warheads to selectively target and kill cancer cells. The firm has multiple PBD-based ADCs in ongoing clinical trials, ranging from first in human to pivotal Phase II clinical trials, and numerous preclinical ADCs in development. Its main drug candidates are ADCT-301 for the treatment of lymphoma and leukemia and ADCT-402 for the treatment of non-Hodgkin’s lymphoma and B-cell leukemia. The company serves customers in the United States, Switzerland, and the United Kingdom.


Biopole, route de la Corniche 3B






CEO & Director
Dr. Ameet Mallik M.B.A., M.S.
Co-Founder & Non-Exec. Director
Dr. Christopher J. Martin DPHIL, Ph.D.
Chief Financial Officer
Ms. Jennifer Creel
Chief Technical Operations Officer
Dr. Michael Mulkerrin Ph.D.
Chief Scientific Officer
Dr. Patrick van Berkel Ph.D.
Investor Relations Officer
Amanda Hamilton
Show More
Chief Compliance & Quality Officer
Ms. Susan Romanus
Chief Legal Officer
Mr. Peter J. Graham Esq.
Sr. VP & Chief People Officer
Ms. Kimberly Pope
Chief Medical Officer
Dr. Joseph Camardo Ph.D.
Show Less

See Also

Other Stocks
What is the Intrinsic Value of one ADCT stock?

The intrinsic value of one ADCT stock under the Base Case scenario is 0.58 USD.

Is ADCT stock undervalued or overvalued?

Compared to the current market price of 0.83 USD, ADC Therapeutics SA is Overvalued by 31%.